New Alzheimer’s Drug Deemed Too Costly for UK’s State-run Health Service
Alzheimer’s patients in Britain’s state-run health service are unlikely to get access to Eisai and Biogen’s new Leqembi drug, after...
Alzheimer’s patients in Britain’s state-run health service are unlikely to get access to Eisai and Biogen’s new Leqembi drug, after...